Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Ibrahim Halil Sahin
Based on 7 articles published since 2009
(Why 7 articles?)

Between 2009 and 2019, I. H. Sahin wrote the following 7 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? 2017

Sahin, I H / Askan, G / Hu, Z I / O'Reilly, E M. ·Department of Medicine, Emory University School of Medicine, Atlanta. · Department of Pathology, Pathology, Memorial Sloan Kettering Cancer Center, New York. · Department of Medicine, Icahn School of Medicine, Mount Sinai Health System, New York. · Department of Medicine, Weill Cornell Medicine, New York, USA. ·Ann Oncol · Pubmed #28945842.

ABSTRACT: The genomic-plasticity of the immune system creates a broad immune repertoire engaged to tackle cancer cells. Promising clinical activity has been observed with several immune therapy strategies in solid tumors including melanoma, lung, kidney, and bladder cancers, albeit as yet immunotherapy-based treatment approaches in pancreatic ductal adenocarcinoma (PDAC) remain to have proven value. While translational and early clinical studies have demonstrated activation of antitumor immunity, most recent late-phase clinical trials have not confirmed the early promise in PDAC except in MSI-High PDAC patients. These results may in part be explained by multiple factors, including the poorly immunogenic nature of PDAC along with immune privilege, the complex tumor microenvironment, and the genetic plasticity of PDAC cells. These challenges have led to disappointments in the field, nonetheless they have also advanced our understanding that may tailor the future steps for immunotherapy for PDAC. Therefore, there is significant hope that progress is on the horizon.

2 Review Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. 2016

Sahin, Ibrahim H / Lowery, Maeve A / Stadler, Zsofia K / Salo-Mullen, Erin / Iacobuzio-Donahue, Christine A / Kelsen, David P / O'Reilly, Eileen M. ·a Department of Medicine , Icahn School of Medicine at Mount Sinai St Luke's Roosevelt Hospital Center , New York , NY , USA. · b Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA. · c Department of Medicine , Weill Cornell Medical College , New York , NY , USA. ·Expert Rev Gastroenterol Hepatol · Pubmed #26881472.

ABSTRACT: Pancreatic cancer is one of the most challenging cancers. Whole genome sequencing studies have been conducted to elucidate the underlying fundamentals underscoring disease behavior. Studies have identified a subgroup of pancreatic cancer patients with distinct molecular and clinical features. Genetic fingerprinting of these tumors is consistent with an unstable genome and defective DNA repair pathways, which creates unique susceptibility to agents inducing DNA damage. BRCA1/2 mutations, both germline and somatic, which lead to impaired DNA repair, are found to be important biomarkers of genomic instability as well as of response to DNA damaging agents. Recent studies have elucidated that PARP inhibitors and platinum agents may be effective to induce tumor regression in solid tumors bearing an unstable genome including pancreatic cancer. In this review we discuss the characteristics of genomic instability in pancreatic cancer along with its clinical implications and the utility of DNA targeting agents particularly PARP inhibitors as a novel treatment approach.

3 Review Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. 2016

Sahin, Ibrahim H / Iacobuzio-Donahue, Christine A / O'Reilly, Eileen M. ·a 1 Icahn School of Medicine at Mount Sinai St Luke's Roosevelt Hospital Center , NY, USA. · b 2 Memorial Sloan Kettering Cancer Center , NY, USA. · c 3 Weill Medical College of Cornell University, David M. Rubenstein Center for Pancreatic Cancer Research , 300 East 66th street, office 1021, NY 10065, USA ; oreillye@mskcc.org. ·Expert Opin Ther Targets · Pubmed #26439702.

ABSTRACT: INTRODUCTION: Pancreatic adenocarcinoma remains one of the most clinically challenging cancers despite an in-depth characterization of the molecular underpinnings and biology of this disease. Recent whole-genome-wide studies have elucidated the diverse and complex genetic alterations which generate a unique oncogenic signature for an individual pancreatic cancer patient and which may explain diverse disease behavior in a clinical setting. AREAS COVERED: In this review article, we discuss the key oncogenic pathways of pancreatic cancer including RAS-MAPK, PI3KCA and TGF-β signaling, as well as the impact of these pathways on the disease behavior and their potential targetability. The role of tumor suppressors particularly BRCA1 and BRCA2 genes and their role in pancreatic cancer treatment are elaborated upon. We further review recent genomic studies and their impact on future pancreatic cancer treatment. EXPERT OPINION: Targeted therapies inhibiting pro-survival pathways have limited impact on pancreatic cancer outcomes. Activation of pro-apoptotic pathways along with suppression of cancer-stem-related pathways may reverse treatment resistance in pancreatic cancer. While targeted therapy or a 'precision medicine' approach in pancreatic adenocarcinoma remains an elusive challenge for the majority of patients, there is a real sense of optimism that the strides made in understanding the molecular underpinnings of this disease will translate into improved outcomes.

4 Article Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. 2018

Sahin, Ibrahim H / Elias, Harold / Chou, Joanne F / Capanu, Marinela / O'Reilly, Eileen M. ·Emory University School of Medicine, Atlanta, USA. · New York University Langone Medical Center, New York, USA. · Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Office 1021, New York, NY, 10065, USA. · Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Office 1021, New York, NY, 10065, USA. oreillye@mskcc.org. · David M. Rubenstein Center for Pancreatic Cancer Research, 300 East 66th Street, Office 1021, New York, NY, 10065, USA. oreillye@mskcc.org. · Weill Cornell Medical College, 300 East 66th Street, Office 1021, New York, NY, 10065, USA. oreillye@mskcc.org. ·BMC Cancer · Pubmed #30055578.

ABSTRACT: BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with high metastatic potential. Clinical observations suggest that there is disease heterogeneity among patients with different sites of distant metastases, yielding distinct clinical outcomes. Herein, we investigate the impact of clinical and pathological parameters on recurrence patterns and compare survival outcomes for patients with a first site of recurrence in the liver versus lung from PDAC following original curative surgical resection. METHODS: Using the Memorial Sloan Kettering Cancer Center ICD billing codes and tumor registry database over a 10 years period (January 2004-December 2014), we identified PDAC patients who underwent resection and subsequently presented with either liver or lung recurrence. Time from relapse to death (TRD) was calculated from date of recurrence to date of death. Using the Kaplan-Meier method, TRD was estimated and compared by recurrence site using log-rank test. RESULTS: The median overall follow-up was 37.3 months among survivors in the entire cohort. Median TRD in this cohort was 10.7 months (95%CI: 8.9-14.6 months). Patients with first site of lung recurrence had a more favorable outcome compared to patients who recurred with liver metastasis as the first site of recurrence (median TRD of 15 versus 9 months respectively, P = 0.02). Moderate to poorly or poor differentiation was associated more often with liver than lung recurrence (40% vs 21% respectively, P = 0.047). A trend to increased lymph node metastasis in the lung recurrence cohort was observed. CONCLUSION: PDAC patients who recur with a first site of lung metastasis have an improved clinical outcome compared to patients with first site of liver recurrence. Our data suggests there may be epidemiologic and pathologic determinants related to patterns of recurrence in PDAC.

5 Article Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. 2016

Sahin, Ibrahim Halil / Geyer, Alexander I / Kelly, Daniel W / O'Reilly, Eileen Mary. ·Mount Sinai Icahn School of Medicine, St Luke's Roosevelt Hospital Center, New York, NY. · Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY. · Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY. Electronic address: oreillye@mskcc.org. ·Clin Colorectal Cancer · Pubmed #26395520.

ABSTRACT: BACKGROUND: Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer patients. PATIENTS AND METHODS: A total 2440 patients at Memorial Sloan Kettering Cancer Center were identified between January 1, 2000, and December 31, 2012, and were screened for grade 2 or higher GRP in an institutional tumor registry and using an ICD billing code database. Demographic and clinical information was extracted by electronic chart review. RESULTS: A total of 28 patients (1.1%) with GRP were identified. Incidence of grade 2, 3, and 4 reactions were 7 (25%), 18 (64%), and 3 (11%), respectively. No GRP-related mortality was observed. Twenty-one patients (75%) reported a history of cigarette smoking. Seventeen patients (61%) were alcohol users. Six patients (21%) were either regular or heavy drinkers. Most patients (93%) had either locally advanced or metastatic disease. Three patients (11%) underwent a diagnostic bronchoscopy, and in 1 patient a diagnosis of organizing pneumonia was established. Morbidity was significant; 3 patients (11%) required treatment in the intensive care unit. All hospitalized patients received steroid treatment. CONCLUSION: GRP is relatively uncommon but incurs significant morbidity. Potential risk factors include advanced-stage disease, along with smoking and alcohol consumption and possibly underlying lung disease. We recommend a high level of clinical alertness regarding the diagnosis, early pulmonary referral, and cessation of gemcitabine on suspicion of GRP.

6 Article Association of diabetes and perineural invasion in pancreatic cancer. 2012

Sahin, Ibrahim Halil / Shama, Mohamed A / Tanaka, Motofumi / Abbruzzese, James L / Curley, Steven A / Hassan, Manal / Li, Donghui. ·Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ·Cancer Med · Pubmed #23342285.

ABSTRACT: Diabetes and perineural invasion are frequently observed in pancreatic cancer. In this study, we tested possible relations between diabetes and perineural invasion in patients with resected pancreatic cancer. We conducted a retrospective study in 544 cases of resected pancreatic adenocarcinoma seen at the University of Texas MD Anderson Cancer Center during 1996-2011. Information on tumor characteristics, diabetes history, and survival time was collected by personal interview and medical record review. Patients with diabetes before or at the time of the pancreatic cancer diagnosis were considered diabetes only. Pearson χ(2) test was used to compare categorical variables in diabetic and nondiabetic groups. Kaplan-Meier plot, log-rank test, and Cox proportional regression models were applied in survival analysis. The prevalence of diabetes and perineural invasion was 26.5% and 86.9%, respectively, in this study population. Patients with diabetes had a significantly higher prevalence of perineural invasion (92.4%) than those without diabetes (85%) (P = 0.025, χ(2) test). Diabetes was not associated with other pathological characteristics of the tumor, such as tumor size, lymphovascular invasion, tumor grade, lymph node metastasis, and resection margin status. Diabetic patients had a significantly lower frequency of abdominal pain (P = 0.01), but a slightly higher frequency of weight loss (P = 0.078) as early symptoms of their cancer. Both diabetes and perineural invasion were related to worse survival and increased risk of death after adjusting for tumor grade and margin and node status (P = 0.036 and 0.019, respectively). The observed associations of diabetes and perineural invasion as well as reduced frequency of pain as early symptom of pancreatic cancer support the hypothesis that diabetes may contribute to pancreatic progression via the mechanism of nerve damage.

7 Minor Comment on: α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. 2015

Sahin, I H / Uzunparmak, B. ·Department of Medicine, Mount Sinai Icahn School of Medicine, St Luke's Roosevelt Hospital Center, New York, NY, USA. · Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ·Br J Cancer · Pubmed #25602961.

ABSTRACT: -- No abstract --